Immuneering Corporation Profile Avatar - Palmy Investing

Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorect…

Biotechnology
US, Cambridge [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of IMRX's Analysis
CIK: 1790340 CUSIP: 45254E107 ISIN: US45254E1073 LEI: - UEI: -
Secondary Listings
IMRX has no secondary listings inside our databases.